enGene’s (ENGN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of enGene (NASDAQ:ENGN) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

ENGN has been the topic of several other reports. Raymond James Financial reissued a “strong-buy” rating and set a $27.00 target price on shares of enGene in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. UBS Group increased their price objective on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, Citizens Jmp upped their target price on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.29.

enGene Stock Performance

Shares of ENGN opened at $7.05 on Monday. The company has a 50-day moving average of $9.54 and a two-hundred day moving average of $8.09. The stock has a market cap of $472.28 million, a price-to-earnings ratio of -3.08 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. enGene has a one year low of $2.65 and a one year high of $12.25.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). On average, equities research analysts expect that enGene will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

Large investors have recently made changes to their positions in the stock. PFS Partners LLC acquired a new position in shares of enGene during the 3rd quarter valued at about $61,000. Cresset Asset Management LLC acquired a new position in enGene during the second quarter valued at approximately $36,000. Raymond James Financial Inc. grew its holdings in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Paloma Partners Management Co bought a new position in shares of enGene in the second quarter valued at approximately $38,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of enGene in the third quarter worth $76,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.